P
Paolo Fiorina
Researcher at Boston Children's Hospital
Publications - 247
Citations - 8816
Paolo Fiorina is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Transplantation & Diabetes mellitus. The author has an hindex of 50, co-authored 216 publications receiving 7280 citations. Previous affiliations of Paolo Fiorina include University of Parma & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Immunomodulation by Mesenchymal Stem Cells A Potential Therapeutic Strategy for Type 1 Diabetes
TL;DR: Recent advances that have broadened the understanding of the immunomodulatory properties of MSC are focused on and insight is provided as to their potential for clinical use as a cell-based therapy for immune-mediated disorders and, in particular, type 1 diabetes.
Journal ArticleDOI
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes.
Paolo Fiorina,Mollie Jurewicz,Andrea Augello,Andrea Vergani,Shirine Dada,Stefano La Rosa,Martin K. Selig,Jonathan G. Godwin,Kenneth Law,Claudia Placidi,R. Neal Smith,Carlo Capella,Scott J. Rodig,Chaker N. Adra,Mark A. Atkinson,Mohamed H. Sayegh,Reza Abdi +16 more
TL;DR: Bone marrow-derived murine MSC is characterized for their ability to modulate immune responses in the context of type 1 diabetes, as represented in NOD mice, to provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.
Journal ArticleDOI
Abatacept in B7-1–Positive Proteinuric Kidney Disease
Chih Chuan Yu,Chih Chuan Yu,Alessia Fornoni,Astrid Weins,Samy Hakroush,Dony Maiguel,Junichiro Sageshima,Linda Chen,Gaetano Ciancio,Mohd Hafeez Faridi,Daniel Behr,Kirk N. Campbell,Jer Ming Chang,Hung Chun Chen,Jun Oh,Christian Faul,M. Amin Arnaout,Paolo Fiorina,Vineet Gupta,Anna Greka,George W. Burke,Peter Mundel +21 more
TL;DR: Data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.
Journal ArticleDOI
A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.
Monika A. Niewczas,Monika A. Niewczas,Meda E. Pavkov,Jan Skupien,Jan Skupien,Adam M. Smiles,Zaipul I. Md Dom,Zaipul I. Md Dom,Jonathan M. Wilson,Jihwan Park,Viji Nair,Andrew Schlafly,Pierre-Jean Saulnier,Pierre-Jean Saulnier,Eiichiro Satake,Eiichiro Satake,Christopher A Simeone,Hetal Shah,Hetal Shah,Chengxiang Qiu,Helen C. Looker,Paolo Fiorina,Paolo Fiorina,Carl F. Ware,Jennifer K. Sun,Jennifer K. Sun,Alessandro Doria,Alessandro Doria,Matthias Kretzler,Katalin Susztak,Kevin L. Duffin,Robert G. Nelson,Andrzej S. Krolewski,Andrzej S. Krolewski +33 more
TL;DR: These findings provide strong evidence that KRIS proteins contribute to the inflammatory process underlying end-stage renal disease development in both types of diabetes, and point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-Stage renal disease.
Journal ArticleDOI
The clinical impact of islet transplantation.
TL;DR: Recent data indicate that restoration of insulin secretion after islet cell transplantation is associated with an improvement in quality of life, with a reduction in hypoglycemic episodes and potentially with a Reduction in long‐term diabetic complications.